Opinion|Videos|August 7, 2024

The Role of ADT in Localized or Locally Advanced Prostate Cancer

Author(s)Lawrence Karsh, MD, FACS, Stephen J. Freedland, MD, Terence Friedlander, MD

3. Terence Friedlander, MD, provides clinical insights on factors that inform the role for androgen deprivation therapy in the treatment of patients with localized or locally advanced prostate cancer.

Episodes in this series

Lawrence Karsh, MD, FACS, an expert on prostate cancer

EP. 1 Prostate Cancer Treatment: The Evolving Therapeutic Landscape

Stephen Freedland, MD, an expert on prostate cancer

EP. 2 The Heterogeneity of Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 3 The Role of ADT in Localized or Locally Advanced Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 4 EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 5 Treatment Considerations in Nonmetastatic CSPC

Terence Friedlander, MD, an expert on prostate cancer

EP. 6 Combination Therapies and Intensifications of ADT in Advanced Prostate Cancer

Terence Friedlander, MD, an expert on prostate cancer

EP. 7 Treatment Options in Castration-Resistant Prostate Cancer

Terence Friedlander, MD, an expert on prostate cancer

EP. 8 The Relationship Between Prostate Cancer and Cardiovascular Disease

Stephen Freedland, MD, an expert on prostate cancer

EP. 9 Impact of GnRH Agonists and Antagonists on Cardiovascular Outcomes in Prostate Cancer

Lawrence Karsh, MD, FACS, an expert on prostate cancer

EP. 10 ADT Treatment Considerations and Unmet Needs in Prostate Cancer

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

ByAdam B. Weiner, MD,Tyler Seibert, MD, PhD

August 21st 2026

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care

ByMary Dunn, MSN, NP-C, OCN, RN

August 20th 2026

SBRT improves multiple quality of life domains but not DFS vs MH-IMRT

ByHannah Clarke

August 18th 2026

Active surveillance use for low-risk prostate cancer reaches 93% in VA system

ByHannah Clarke

August 14th 2026

Focal therapy for prostate cancer frequently used outside guideline-supported groups

ByHannah Clarke

August 14th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care